Relations between universities and industry have changed considerably over the past 35 years, largely due to new models of research and development pioneered in the life sciences and the biotech sector. In this 90-minute discussion, Genentech founder Herb Boyer and co-inventor of recombinant DNA technology Stan Cohen will be joined by an esteemed panel who drove the sweeping changes between academia and industry during these pivotal years and reflect on its impact for today. The discussion will be followed by a reception.
The patenting of recombinant DNA technology and the founding of Genentech in the mid-1970s were pivotal events that sparked controversy and catalyzed sweeping changes in the sciences, universities, the pharmaceutical industry, and government science policy. Today, policymakers continue to seek optimal configurations for fostering scientific progress, technology transfers, industrial innovation, and economic development. The panel will reflect on changing ideas about the ‘purity’ of science and the ethics of research privatization since the 1970s. They will also discuss today’s ecosystems for interdisciplinary research, translational medicine, and faculty entrepreneurship between academia and industry .
Joining Herb Boyer and Stan Cohen are Regis Kelly of QB3 and Keith Yamamoto vice chancellor for research, executive vice dean of the School of Medicine, and professor of cellular and molecular pharmacology from UCSF and Kathy Ku and Niels Reimers from Stanford’s Office of Technology Licensing. David Ewing Duncan will moderate the discussion. He is an award-winning, best-selling author of six books, his work has appeared in Atlantic Monthly, Smithsonian, National Geographic, The Telegraph, The Guardian, The Washington Post Book World, The San Francisco Chronicle, and The New York Times. He is a chief correspondent of NPR’s Biotech Nation and has been a special correspondent for ABC’s Nightline and 20/20, NOVA’s ScienceNow!, and a producer for Discovery Television.